亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會(huì)員第1年

南京克萊森醫(yī)藥化工有限公司  

普瑞巴林中間體，替卡格雷中間體，達(dá)比加群酯中間體，羅匹尼羅中間體，利克飛龍中間體，阿扎那韋中間體，拉帕替尼中間體，埃羅替尼中間體，伐侖克林中間體，地瑞那韋中間體，阿替美唑中間體，依替米貝中間體
搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人：徐罡
  • 電話：025-83172646
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 阿扎那韋中間體127406-56-8
阿扎那韋中間體127406-56-8
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 江蘇南京市付款后3天內(nèi)
型號(hào) 127406-56-8
規(guī)格 127406-56-8
過期 長(zhǎng)期有效
更新 2012-05-31 16:55
 
詳細(xì)信息

4-(2-Pyridinyl)benzaldehyde    4-(2-吡啶基)-苯甲醛阿扎那韋中間體2            cas 127406-56-8              
Name of product：4-(2-Pyridinyl)benzaldehyde             
CAS No：127406-56-8
Formula：C12H9NO
Molecular Weight：183.21
©2025 南京克萊森醫(yī)藥化工有限公司 版權(quán)所有   技術(shù)支持：化工網(wǎng)   訪問量:9969  
 
主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |